Left vs Left Randomized Clinical Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBaylor College of Medicine

About this trial

The investigators aim to prospectively test the comparative effectiveness of His or Left bundle branch pacing in relation to patient centered outcomes (quality of life, physical activity, heart failure hospitalization, mortality) and comparative safety in relation to device-related complications and re-interventions (e.g., lead dislodgement, infection) relative to standard of care biventricular pacing in patients with heart failure due to left ventricular systolic dysfunction (LVEF≤50%) and with either a wide QRS (≥130 ms) or with/anticipated \>40% pacing who are already receiving current standard heart failure pharmacological therapy.

Eligibility criteria

Qualifiers

Men and women 18 years of age or older.

A LVEF ≤ 50% within 6 months prior to enrollment.

Resting QRS duration ≥130 ms as evidenced by a historical 12-lead ECG prior to enrollment OR anticipated right ventricular pacing >40% OR device in place with right ventricular pacing > 40%.

Are optimized on HF guideline directed medical therapy according to current HF published guidelines OR patient's physician will make an effort to start all guideline-directed medical therapy and titrate doses up as permitted by the participant clinical status and co-morbidities prior to implantation procedure.

Disqualifiers

Women who are pregnant, lactating, or plan to become pregnant during the course of the trial.

Participants with angiographic evidence of coronary disease who are candidates for coronary revascularization and are likely to undergo coronary artery bypass graft surgery or percutaneous coronary, intervention in the next three (3) months.

Enzyme-positive myocardial infarction within the past three (3) months prior to enrollment.

Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon and/or stent angioplasty) within the past three (3) months prior to enrollment.

Trial design

Treatments tested in this trial

  • His/LBBP
  • BiVP

Treatment groups

2,136 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Baylor College of Medicine

Lead sponsor

Patient-Centered Outcomes Research Institute

Collaborator

University of Utah

Collaborator

Virginia Commonwealth University

Collaborator

Cleveland Clinic Florida

Collaborator

East Carolina University

Collaborator